tirzepatide vs retatrutide dosage Schedule After High Dose Tirzepatide vs. Retatrutide: Key Differences

125 LuS

This trial set the standard for anti-obesity incretin mimetics and launched the commercialization of Wegovy

Over the past two decades, therapies based on incretin hormones, spearheaded by glucagon-like peptide 1 (GLP1) receptor agonists (GLP1RAs), have become the treatment of choice for obesity and T2DM, and clinical evidence now suggests that these agents have benefits for CVD

You are building tissue concentrations and assessing tolerance, not yet achieving therapeutic effects

Noteworthily, we observed that long-acting GLP-1 RAs offer more pronounced benefits, potentially due to their sustained pharmacological action, suggesting a dependency on pharmacokinetic profiles for maximal therapeutic impact